
Altevax SAS
MABDESIGN MEMBER
About us
Altevax is developing a first-in-class immunotherapy using melanin as an adjuvant. When linked to a disease-specific antigen using our technology, melanin helps trigger a strong, antigen-specific immune response of the CD8+ T cells.
Know-how
neuro oncology; clinical trials; in vivo models
Business offer
Glioblastoma immunotherapy & co-development or licensing for indications other than glioblastoma
Field of application
- cellular immunotherapy
- therapeutic vaccines
Therapeutic application
- infectiology
- immunology
- oncology
Expertise
- Target Selection & Validation
- Gene / protein discovery
- bioinformatics design
- Assay development in in-vitro & in-vivo models
- Immunotherapy Hit Discovery
- Screening & Identification
- In-vivo models
- Immunotherapy Lead Generation
- Epitope mapping
- Pharmacology & Biological activity
- PK/PD bioavailability
- Mode of Action
- Therapeutic efficacy
- Safety
- Specificity
- Cell activation
- Cell-based activation (APCs, AAPCs)
- In-vivo activation (in human transgenic mouse models)
- Immunotherapy Lead Optimization
- Proof of concept
- in-vivo models
- Clinical Trials
- Phase I
- Phase II
- Regulatory Filing
- Regulatory Filing
Category
- Therapeutic product
Contact
- Victor Vadaneaux
CEO - 55 Avenue Marceau 75116 Paris
- +33 7 56 96 03 40
- victor.vadaneaux@altevax.com
- www.altevax.com/